• 1
    Stetler-Stevenson WG,Aznavoorian S,Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 54173.
  • 2
    Liotta LA,Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 3759.
  • 3
    Sidenius N,Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 20522.
  • 4
    Deryugina EI,Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 934.
  • 5
    Mohamed MM,Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 76475.
  • 6
    Poole AR,Tiltman KJ,Recklies AD,Stoker TA. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273: 5457.
  • 7
    Ghosh P,Dahms NM,Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003; 4: 20212.
  • 8
    Achkar C,Gong QM,Frankfater A,Bajkowski AS. Differences in targeting and secretion of cathepsins B and L by BALB/3T3 fibroblasts and Moloney murine sarcoma virus-transformed BALB/3T3 fibroblasts. J Biol Chem 1990; 265: 136504.
  • 9
    Capony F,Braulke T,Rougeot C,Roux S,Montcourrier P,Rochefort H. Specific mannose-6-phosphate receptor-independent sorting of pro-cathepsin D in breast cancer cells. Exp Cell Res 1994; 215: 15463.
  • 10
    Lorenzo K,Ton P,Clark JL,Coulibaly S,Mach L. Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin-like growth factor II receptor. Cancer Res 2000; 60: 40706.
  • 11
    Ludwig T,Munier-Lehmann H,Bauer U,Hollinshead M,Ovitt C,Lobel P,Hoflack B. Differential sorting of lysosomal enzymes in mannose 6-phosphate receptor-deficient fibroblasts. EMBO J 1994; 13: 34307.
  • 12
    Pohlmann R,Wendland M,Boeker C,von Figura K. The two mannose 6-phosphate receptors transport distinct complements of lysosomal proteins. J Biol Chem 1995; 270: 2731118.
  • 13
    Kiess W,Blickenstaff GD,Sklar MM,Thomas CL,Nissley SP,Sahagian GG. Biochemical evidence that the type II insulin-like growth factor receptor is identical to the cation-independent mannose 6-phosphate receptor. J Biol Chem 1988; 263: 933944.
  • 14
    Kovacina KS,Steele-Perkins G,Purchio AF,Lioubin M,Miyazono K,Heldin CH,Roth RA. Interactions of recombinant and platelet transforming growth factor-β1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor. Biochem Biophys Res Commun 1989; 160: 393403.
  • 15
    Nykjaer A,Christensen EI,Vorum H,Hager H,Petersen CM,Roigaard H,Min HY,Vilhardt F,Moller LB,Kornfeld S,Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol 1998; 141: 81528.
  • 16
    Godar S,Horejsi V,Weidle UH,Binder BR,Hansmann C,Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1. Eur J Immunol 1999; 29: 100413.
  • 17
    Jirtle RL. Genomic imprinting and cancer. Exp Cell Res 1999; 248: 1824.
  • 18
    Kong FM,Anscher MS,Washington MK,Killian JK,Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2000; 19: 15728.
  • 19
    Jamieson TA,Brizel DM,Killian JK,Oka Y,Jang H-S,Fu X,Clough RW,Vollmer RT,Anscher MS,Jirtle RL. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer 2003; 3: 4.
  • 20
    Byrd JC,Devi GR,de Souza AT,Jirtle RL,MacDonald RG. Disruption of ligand binding to the insulin-like growth factor II/mannose-6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 1999; 274: 2440816.
  • 21
    Devi GR,De Souza AT,Byrd JC,Jirtle RL,MacDonald RG. Altered ligand binding by insulin-like growth factor II/mannose-6-phosphate receptors bearing missense mutations in human cancer. Cancer Res 1999; 59: 431419.
  • 22
    Wise TL,Pravtcheva DD. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 2006; 66: 132736.
  • 23
    O'Gorman DB,Weiss J,Hettiaratchi A,Firth SM,Scott CD. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 2002; 143: 428794.
  • 24
    Lee JS,Weiss J,Martin JL,Scott CD. Increased expression of the mannose-6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 2003; 107: 56470.
  • 25
    Li J,Sahagian GG. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 2004; 23: 935968.
  • 26
    Souza RF,Wang S,Thakar M,Smolinski KN,Yin J,Zou TT,Kong D,Abraham JM,Toretsky JA,Meltzer SJ. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18: 40638.
  • 27
    O'Gorman DB,Costello M,Weiss J,Firth SM,Scott CD. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res 1999; 59: 56924.
  • 28
    Chen Z,Ge Y,Landman N,Kang JX. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2002; 2: 18.
  • 29
    Coulibaly S,Schwihla H,Abrahamson M,Albini A,Cerni C,Clark JL,Ng KM,Katunuma N,Schlappack O,Glössl J,Mach L. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int J Cancer 1999; 83: 52631.
  • 30
    Probst OC,Ton P,Svoboda B,Gannon A,Schuhmann W,Wieser J,Pohlmann R,Mach L. The 46-kDa mannose 6-phosphate receptor does not depend on endosomal acidification for delivery of hydrolases to lysosomes. J Cell Sci 2006; 119: 493543.
  • 31
    Leksa V,Godar S,Cebecauer M,Hilgert I,Breuss J,Weidle UH,Horejsi V,Binder BR,Stockinger H. The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J Biol Chem 2002; 277: 4057582.
  • 32
    Klumperman J,Hille A,Veenendaal T,Oorschot V,Stoorvogel W,von Figura K,Geuze HJ. Differences in the endosomal distributions of the two mannose 6-phosphate receptors. J Cell Biol 1993; 121: 9971010.
  • 33
    Dennes A,Cromme C,Suresh K,Kumar NS,Eble JA,Hahnenkamp A,Pohlmann R. The novel Drosophila lysosomal enzyme receptor protein mediates lysosomal sorting in mammalian cells and binds mammalian and Drosophila GGA adaptors. J Biol Chem 2005; 280: 1284957.
  • 34
    Mach L,Stüwe K,Hagen A,Ballaun C,Glössl J. Proteolytic processing of cathepsin B. The role of the primary structure of the latent precursor and of the carbohydrate moiety for cell-type-specific molecular forms of the enzyme. Biochem J 1992; 282: 57782.
  • 35
    Schmid JA,Mach L,Paschke E,Glössl J. Accumulation of sialic acid in endocytic compartments interferes with the formation of mature lysosomes. J Biol Chem 1999; 274: 1906371.
  • 36
    Albini A,Iwamoto Y,Kleinman HK,Martin GR,Aaronson SA,Kozlowski JM,McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 323945.
  • 37
    Wenk J,Hille A,von Figura K. Quantitation of Mr 46,000 and Mr 300,000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int 1991; 23: 72332.
  • 38
    Chavez CA,Bohnsack RN,Kudo M,Gotschall RR,Canfield WM,Dahms NM. Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters (mannose 6-phosphate N-acetylglucosamine ester). Biochemistry 2007; 46: 1260417.
  • 39
    Dong JM,Prence EM,Sahagian GG. Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts. J Biol Chem 1989; 264: 737783.
  • 40
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 41
    De Souza AT,Hankins GR,Washington MK,Orton TC,Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 4479.
  • 42
    Yamada T,De Souza AT,Finkelstein S,Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997; 94: 103515.
  • 43
    Hankins GR,De Souza AT,Bentley RC,Patel MR,Marks JR,Iglehart JD,Jirtle RL. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12: 20039.
  • 44
    Schaffer BS,Lin MF,Byrd JC,Park JH,MacDonald RG. Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells. Endocrinology 2003; 144: 95566.
  • 45
    Rosenthal EL,Johnson TM,Allen ED,Apel IJ,Punturieri A,Weiss SJ. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 1998; 58: 522130.
  • 46
    Hotary K,Li XY,Allen E,Stevens SL,Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006; 20: 267386.
  • 47
    Joyce JA,Baruch A,Chehade K,Meyer-Morse N,Giraudo E,Tsai FY,Greenbaum DC,Hager JH,Bogyo M,Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 44353.
  • 48
    Lakka SS,Gondi CS,Yanamandra N,Olivero WC,Dinh DH,Gujrati M,Rao JS. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23: 46819.
  • 49
    Gocheva V,Zeng W,Ke D,Klimstra D,Reinheckel T,Peters C,Hanahan D,Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 54356.